Christopher Flowers, MD
Hematology & Oncology · Houston, TXNPI 1174630503
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $192,940 of the $219,924 with a category attached, or 87.7%. 19 manufacturers reported payments, led by Genentech, Inc. at 32.4% of the total. Reporting peaked in 2023 at $81,507 and has fallen 91.4% since, to $6,979 in 2025. Among hematology & oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 81 payments — averaging $2715.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$71K
- Chugai Pharmaceutical Co., Ltd.$70K
- Morphosys AG$17K
- Beigene Switzerland GmbH$14K
- Beigene USA, Inc.$11K
- F. Hoffmann-la Roche AG$11K
- plus $26K from 13 others
Across 74 payments — averaging $230,414 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$10.5M
- Mirati Therapeutics, Inc.$3.2M
- Pfizer$1.8M
- Jazz Pharmaceuticals Inc.$1M
- Myriad Genetic Laboratories, Inc.$500K
- Merck$50K
- plus $31K from 2 others
What the payments were for
- Consulting fees$192,94088%
- Speaking & faculty fees$9,5914%
- Travel & lodging$14,9607%
- Food & beverage$2,4331%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 19 | $71,256 |
| Chugai Pharmaceutical Co., Ltd. | 7 | $69,752 |
| Morphosys AG | 6 | $17,390 |
| Beigene Switzerland GmbH | 3 | $13,805 |
| Beigene USA, Inc. | 3 | $11,427 |
| F. Hoffmann-la Roche AG | 12 | $10,755 |
| Bristol Myers Squibb | 3 | $6,466 |
| Seagen Inc. | 3 | $5,763 |
| Genentech USA, Inc. | 6 | $3,157 |
| Epizyme, Inc. | 1 | $2,900 |
| ADC Therapeutics America, Inc. | 2 | $2,558 |
| Incyte Corporation | 2 | $2,365 |
| AbbVie | 3 | $1,466 |
| Stryker | 5 | $238 |
| Merck | 2 | $180 |
| Beone Medicines USA, Inc. | 1 | $168 |
| Trisalus Life Sciences, Inc. | 1 | $154 |
| Gilead | 1 | $103 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- POLIVY$36,444
- BRUKINSA$19,142
- Columvi$13,640
- MONJUVI$10,780
- Non-Covered Product$7,032
- ADCETRIS$5,763
- TAZVERIK$2,900
- Lunsumio$2,850
- TRINAV INFUSION SYSTEM$154
- Yescarta$103
How this compares
$219,924 in reported general payments places this provider in the 95th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Houston
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Naval DaverHouston$853K
- Jorge Cortes-FrancoHouston$627K
- Courtney DinardoHouston$478K
- Prithviraj BoseHouston$463K
- Milind JavleHouston$326K
- Loretta NastoupilHouston$309K
- Boyu HuHouston$281K
- Luis CamachoHouston$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.